← Eichor
Condition: Acute Severe Ulcerative Colitis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Acute Severe Ulcerative Colitis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Phase N/A · 1 location(s) · Brain Inflammation Collaborative · NCT04806620
Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis(U
Phase 4 · 4 location(s) · Yongquan Shi · NCT07546097
Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis(UPRISE)
Phase 4 · 4 location(s) · Xijing Hospital of Digestive Diseases · NCT07550673
Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis
Phase 4 · 1 location(s) · Berinstein, Jeffrey · NCT05867329
Study of Novel Therapeutics for Acute Remedy of Colitis
Phase 2 · 2 location(s) · Brigham and Women's Hospital · NCT06420492
Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis
Phase 3 · 1 location(s) · McMaster University · NCT06660693
Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With A
Phase 4 · 1 location(s) · Berinstein, Jeffrey · NCT07258771
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.